A Facile Approach to Enhance Antigen Response for Personalized Cancer Vaccination

Overview

Journal Nat Mater

Date 2018 Mar 7

PMID 29507416

Citations 137

Authors

Aileen Weiwei Li

Miguel C Sobral

Soumya Badrinath

Youngjin Choi

Amanda Graveline

Alexander G Stafford

James C Weaver

Maxence O Dellacherie

Ting-Yu Shih

Omar A Ali

Jaeyun Kim

Kai W Wucherpfennig

David J Mooney

Affiliations

Soon will be listed here.

Abstract

Existing strategies to enhance peptide immunogenicity for cancer vaccination generally require direct peptide alteration, which, beyond practical issues, may impact peptide presentation and result in vaccine variability. Here, we report a simple adsorption approach using polyethyleneimine (PEI) in a mesoporous silica microrod (MSR) vaccine to enhance antigen immunogenicity. The MSR-PEI vaccine significantly enhanced host dendritic cell activation and T-cell response over the existing MSR vaccine and bolus vaccine formulations. Impressively, a single injection of the MSR-PEI vaccine using an E7 peptide completely eradicated large, established TC-1 tumours in about 80% of mice and generated immunological memory. When immunized with a pool of B16F10 or CT26 neoantigens, the MSR-PEI vaccine eradicated established lung metastases, controlled tumour growth and synergized with anti-CTLA4 therapy. Our findings from three independent tumour models suggest that the MSR-PEI vaccine approach may serve as a facile and powerful multi-antigen platform to enable robust personalized cancer vaccination.

Citing Articles

Immune Cell Homing Hydrogels for Cancer Immunotherapy.

Han J, Wang H Methods Mol Biol. 2025; 2902:107-116.

PMID: 40029598 DOI: 10.1007/978-1-0716-4402-7_6.

Enhanced Cancer Immunotherapy by Bacterial Cytoplasmic Membranes Coated Nanovaccines for Co-Delivery of Ovalbumin Antigen and Immune Adjuvants to Dendritic Cells in Lymph Nodes.

Zhao P, Fan Y, Wang Z, Tang H, Tian Y, Zhang Y Int J Nanomedicine. 2025; 20:2289-2304.

PMID: 40007905 PMC: 11853991. DOI: 10.2147/IJN.S496873.

Targeting vaccines to dendritic cells by mimicking the processing and presentation of antigens in xenotransplant rejection.

Wang J, Zhang Y, Jia Y, Xing H, Xu F, Xia B Nat Biomed Eng. 2025; 9(2):201-214.

PMID: 39948171 DOI: 10.1038/s41551-025-01343-6.

Advances in molecular imaging and targeted therapeutics for lymph node metastasis in cancer: a comprehensive review.

Wu Y, Shang J, Zhang X, Li N J Nanobiotechnology. 2024; 22(1):783.

PMID: 39702277 PMC: 11657939. DOI: 10.1186/s12951-024-02940-4.

A Purely Biomanufactured System for Delivering Nanoparticles and STING Agonists.

Li Y, Feng Y, Li W, Zhang Y, Sun Y, Wang S Adv Sci (Weinh). 2024; 12(3):e2408539.

PMID: 39588587 PMC: 11744655. DOI: 10.1002/advs.202408539.

References

Kim J, Li W, Sands W, Mooney D . Effect of pore structure of macroporous poly(lactide-co-glycolide) scaffolds on the in vivo enrichment of dendritic cells. ACS Appl Mater Interfaces. 2014; 6(11):8505-12. PMC: 4056860. DOI: 10.1021/am501376n. View

Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J . Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015; 520(7549):692-6. PMC: 4838069. DOI: 10.1038/nature14426. View

van der Burg S, Arens R, Ossendorp F, van Hall T, Melief C . Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer. 2016; 16(4):219-33. DOI: 10.1038/nrc.2016.16. View

Ott P, Hu Z, Keskin D, Shukla S, Sun J, Bozym D . An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017; 547(7662):217-221. PMC: 5577644. DOI: 10.1038/nature22991. View

Li W, Lu B, Gu L, Choi Y, Kim J, Mooney D . The effect of surface modification of mesoporous silica micro-rod scaffold on immune cell activation and infiltration. Biomaterials. 2016; 83:249-56. PMC: 4754159. DOI: 10.1016/j.biomaterials.2016.01.026. View

Liu H, Moynihan K, Zheng Y, Szeto G, Li A, Huang B . Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014; 507(7493):519-22. PMC: 4069155. DOI: 10.1038/nature12978. View

Song W, Du J, Sun T, Zhang P, Wang J . Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery. Small. 2009; 6(2):239-46. DOI: 10.1002/smll.200901513. View

van der Sluis T, Sluijter M, van Duikeren S, West B, Melief C, Arens R . Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression. Cancer Immunol Res. 2015; 3(9):1042-51. DOI: 10.1158/2326-6066.CIR-15-0052. View

Moon J, Suh H, Bershteyn A, Stephan M, Liu H, Huang B . Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater. 2011; 10(3):243-51. PMC: 3077947. DOI: 10.1038/nmat2960. View

10.

Eisenbarth S, Colegio O, OConnor W, Sutterwala F, Flavell R . Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008; 453(7198):1122-6. PMC: 4804622. DOI: 10.1038/nature06939. View

11.

Chaturvedi A . Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010; 46(4 Suppl):S20-6. DOI: 10.1016/j.jadohealth.2010.01.016. View

12.

Vollmer J, Krieg A . Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev. 2009; 61(3):195-204. DOI: 10.1016/j.addr.2008.12.008. View

13.

Mulens-Arias V, Rojas J, Perez-Yague S, Morales M, Barber D . Polyethylenimine-coated SPIONs trigger macrophage activation through TLR-4 signaling and ROS production and modulate podosome dynamics. Biomaterials. 2015; 52:494-506. DOI: 10.1016/j.biomaterials.2015.02.068. View

14.

Hornung V, Bauernfeind F, Halle A, Samstad E, Kono H, Rock K . Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008; 9(8):847-56. PMC: 2834784. DOI: 10.1038/ni.1631. View

15.

Hopken U, Lehmann I, Droese J, Lipp M, Schuler T, Rehm A . The ratio between dendritic cells and T cells determines the outcome of their encounter: proliferation versus deletion. Eur J Immunol. 2005; 35(10):2851-63. DOI: 10.1002/eji.200526298. View

16.

Gubin M, Artyomov M, Mardis E, Schreiber R . Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015; 125(9):3413-21. PMC: 4588307. DOI: 10.1172/JCI80008. View

17.

Sakai S, Yamada Y, Yamaguchi T, Ciach T, Kawakami K . Surface immobilization of poly(ethyleneimine) and plasmid DNA on electrospun poly(L-lactic acid) fibrous mats using a layer-by-layer approach for gene delivery. J Biomed Mater Res A. 2008; 88(2):281-7. DOI: 10.1002/jbm.a.31870. View

18.

Cho N, Cheong T, Min J, Wu J, Lee S, Kim D . A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy. Nat Nanotechnol. 2011; 6(10):675-82. DOI: 10.1038/nnano.2011.149. View

19.

Zhou P, Shaffer D, Alvarez Arias D, Nakazaki Y, Pos W, Torres A . In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature. 2014; 506(7486):52-7. PMC: 4052214. DOI: 10.1038/nature12988. View

20.

Oh Y, Park J, Kang M, Ko J, Kim J, Kim C . Enhanced adjuvanticity of interleukin-2 plasmid DNA administered in polyethylenimine complexes. Vaccine. 2003; 21(21-22):2837-43. DOI: 10.1016/s0264-410x(03)00178-6. View